Related Experiment Video
Updated: Jul 12, 2025
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.2K
Ivosidenib in acute myeloid leukemia
Antonella Bruzzese1, Caterina Labanca1, Enrica Antonia Martino1
1Department of Onco-Hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
Expert Opinion on Pharmacotherapy
|October 24, 2023
Summary
Ivosidenib, an IDH1 inhibitor, shows promise in treating acute myeloid leukemia (AML) by inducing differentiation and offering a strong safety profile. It is effective alone or with chemotherapy, positioning it for combination therapies.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute myeloid leukemia (AML) treatment has relied on chemotherapy for decades.
- Recent advancements include targeted therapies like hypomethylating agents and small molecules.
- New drugs include Bcl2 inhibitor venetoclax, FLT3 inhibitors, IDH1/IDH2 inhibitors, and hedgehog pathway inhibitors.
Purpose of the Study:
- To review the role of ivosidenib in AML treatment.
- To highlight its efficacy, safety, and potential in combination therapies.
- To discuss strategies for overcoming resistance.
Main Methods:
- Review of clinical data and preclinical studies on ivosidenib.
- Analysis of ivosidenib's mechanism of action as an IDH1R132 inhibitor.
- Evaluation of its safety and efficacy in monotherapy and combination settings.
Main Results:
- Ivosidenib induces differentiation in mIDH1 AML blasts.
- It demonstrates an exceptional safety profile.
- Clinical data show effectiveness in monotherapy and combination strategies.
Conclusions:
- Ivosidenib's safety and efficacy make it suitable for combination with chemotherapy, hypomethylating agents, or venetoclax.
- Further research is needed to address ivosidenib resistance.
- Ivosidenib represents a significant advancement in AML therapeutics.
Related Concept Videos
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
19
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
19
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
305
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
305
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K